Traxoprodil


NR2B subunit-selective N-methyl-D-aspartate receptor antagonist

A second-generation phenylethanol amine ifenprodil derivative developed at Pfizer as a forebrain-selective neuroprotectant, distinguished from first-generation NR2B antagonists by absence of alpha-1 adrenergic receptor activity and clinically evaluated in traumatic brain injury, treatment-resistant major depression, and levodopa-induced dyskinesia in Parkinson’s disease.

Abstract

Traxoprodil (CP-101,606) is a potent and selective antagonist of N-methyl-D-aspartate (NMDA) receptors containing the NR2B (GluN2B) subunit, originally synthesized at the Central Research Division of Pfizer Inc. in Groton, Connecticut, and first disclosed by Chenard et al. in 1995 as a neuroprotectant with high selectivity for forebrain neurons. Structurally a substituted 4-phenylpiperidine and single-isomer phenylethanol amine derivative of the first-generation NR2B antagonist ifenprodil, traxoprodil retains the high-affinity NR2B binding (KD of 4.2 nanomolar in adult rodent forebrain) while eliminating the alpha-1 adrenergic receptor activity that limited the clinical utility of its predecessor. The compound binds at the amino-terminal domain interface of the NR1/NR2B heterodimer and inhibits channel opening by enhancing tonic proton inhibition, a mechanism formally characterized by Mott et al. (1998) that distinguishes the phenylethanol amine class from channel-blocking NMDA antagonists such as ketamine and memantine. The nonlinear, dose-dependent oral pharmacokinetics in extensive metabolizers reflect saturation of hepatic first-pass CYP2D6 metabolism; at high oral doses the impact of CYP2D6 polymorphism on exposure diminishes as the enzyme saturates. The compound was advanced through three principal clinical programs. In traumatic brain injury, an open-label study of 30 patients with severe head injury or spontaneous intracerebral hemorrhage demonstrated safety, tolerability, and 80 percent good recovery at 3 months; a subsequent randomized, double-blind, placebo-controlled Phase 2/3 trial of 404 severe TBI patients showed trends toward improved functional outcome (7.5 percent improvement on the dichotomized Glasgow Outcome Scale, p = 0.07) and reduced mortality (7 percent difference, p = 0.08) but did not reach conventional statistical significance. In treatment-resistant major depression, a randomized, double-blind, placebo-controlled proof-of-concept trial of 30 paroxetine-nonresponders demonstrated a 60 percent response rate on the Hamilton Depression Rating Scale after a single intravenous infusion of CP-101,606 versus 20 percent on placebo, with 78 percent of responders maintaining response for at least one week, and without dissociative side effects. In Parkinson’s disease, a double-blind crossover trial in 12 patients showed approximately 30 percent reduction in levodopa-induced dyskinesia but dose-dependent dissociative and amnestic adverse events. Clinical development was ultimately discontinued due to cardiovascular safety concerns, specifically QTc interval prolongation attributed to inhibition of the human ether-a-go-go-related gene (hERG) potassium channel, a liability that Pfizer determined precluded further advancement. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph